MARKET

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

2.225
+0.055
+2.53%
Opening 15:38 05/14 EDT
OPEN
2.260
PREV CLOSE
2.170
HIGH
2.380
LOW
2.210
VOLUME
632.04K
TURNOVER
--
52 WEEK HIGH
3.132
52 WEEK LOW
0.7299
MARKET CAP
359.64M
P/E (TTM)
-16.1466
1D
5D
1M
3M
1Y
5Y
BRIEF-Lineage Reports First Quarter 2021 Financial Results And Highlights Significant Progress With All Three Clinical Programs
reuters.com · 22h ago
Lineage Cell Therapeutics Q1 EPS $(0.01) Beats $(0.04) Estimate, Sales $400.00K Miss $790.00K Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.04) by 75 percent. This is a 83.33 percent increase over losses of $(0.06) per share
Benzinga · 22h ago
Lineage Cell Therapeutics EPS beats by $0.03, misses on revenue
Lineage Cell Therapeutics (LCTX): Q1 GAAP EPS of -$0.01 beats by $0.03.Revenue of $0.39M (-23.5% Y/Y) misses by $0.2M.Current Cash and Marketable Securities Expected to Support Operations Well Into 2023.Press
Seekingalpha · 23h ago
Lineage Cell Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Lineage Cell Therapeutics, Inc. (AMEX:LCTX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 1d ago
Lineage Cell Therapeutics Q1 Loss Narrows, Revenue Falls
MT Newswires · 1d ago
-- Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $391,000, vs. Street Est of $0.593M
MT Newswires · 1d ago
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 1d ago
Lineage Cell (LCTX) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LCTX. Analyze the recent business situations of Lineage Cell Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LCTX stock price target is 5.33 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 118
Institutional Holdings: 66.40M
% Owned: 41.08%
Shares Outstanding: 161.64M
TypeInstitutionsShares
Increased
29
919.96K
New
11
1.63M
Decreased
26
988.89K
Sold Out
19
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.90%
Pharmaceuticals & Medical Research
+1.20%
Key Executives
Chairman/Director
Alfred Kingsley
Chief Executive Officer/Chief Financial Officer/Director
Brian Culley
Finance Director/Chief Accounting Officer/Controller
Alexandra Hernandez
Senior Vice President
Gary Hogge
Independent Director
Dipti Amin
Independent Director
Deborah Andrews
Independent Director
Don Bailey
Independent Director
Neal Bradsher
Independent Director
Stephen Farrell
Independent Director
Anula Jayasuriya
Independent Director
Michael Mulroy
Independent Director
Angus Russell
No Data
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. It has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is a cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

Webull offers kinds of Lineage Cell Therapeutics Inc stock information, including AMEX:LCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCTX stock methods without spending real money on the virtual paper trading platform.